Johnson & Johnson's oral IL-23 inhibitor Icotyde, tipped to become a future blockbuster, has been recommended as a frontline ...
China-based Innocare Pharma said on Monday the Phase III trial of fadeucravacitinib, an experimental treatment for moderate-to-severe plaque psoriasis, has met its primary endpoint.
Psoriasis is a chronic inflammatory skin disease affecting more than 60 million people worldwide, characterized by painful ...
Health experts say recognizing the first symptoms of psoriasis and adopting anti-inflammatory lifestyle habits early may help ...
Adults with psoriasis of varying degrees show a higher burden of myocardial dysfunction than control individuals, a study ...
People with moderate-to-severe plaque psoriasis in Europe could soon gain access to the first oral medicine targeting the interleukin (IL)-23 pathway, after the European Medicines Agency’s (EMA) ...
Add Yahoo as a preferred source to see more of our stories on Google. More than eight million people in the United States have the autoimmune skin condition known as psoriasis, according to the ...
LATITUDE PsO 3001/3002 (n = 693; n = 1108) showed ~70% of patients achieving clear or almost clear skin at week 16 versus 11% to 13% on placebo and 30% to 32% on apremilast. Depth of response was ...
Patients who were prescribed GLP-1 receptor agonists for type 2 diabetes demonstrated increased risks for psoriatic arthritis ...
WHEN Mersadies La Caze suddenly noticed red spots in the centre of her back six months into her pregnancy, she dismissed it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results